for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

18.44USD

Change

0.11(+0.60%)

Volume

203,316

Today's Range

17.59

 - 

18.72

52 Week Range

4.52

 - 

28.16

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Atara Biotherapeutics Announces Proposed Offering Of Common Stock

Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK.

Bayer, Atara Biotherapeutics Enter Pact For Car T-Cell Therapies

Dec 7 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::BAYER AND ATARA BIOTHERAPEUTICS ENTER STRATEGIC COLLABORATION FOR MESOTHELIN-TARGETED CAR T-CELL THERAPIES FOR SOLID TUMORS.ATARA BIOTHERAPEUTICS INC - COLLABORATION WILL FOCUS ON OFF-THE-SHELF T-CELL IMMUNOTHERAPY ATA3271 FOR HIGH MESOTHELIN-EXPRESSING TUMORS.ATARA BIOTHERAPEUTICS - BAYER TO ENTER CAR T-CELL THERAPY SPACE, EXPAND ONCOLOGY DEVELOPMENT.ATARA - TO RECEIVE UPFRONT PAYMENT OF $ 60 MILLION, AND UP TO TOTAL OF $610 MILLION FOR DEVELOPMENT, REGULATORY & COMMERCIALIZATION MILESTONES.ATARA BIOTHERAPEUTICS INC - ATARA WILL LEAD IND (INVESTIGATIONAL NEW DRUG)-ENABLING STUDIES AND PROCESS DEVELOPMENT FOR ATA3271.ATARA BIOTHERAPEUTICS INC - BAYER WILL BE RESPONSIBLE FOR SUBMITTING THE IND AND SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALIZATION.ATARA BIOTHERAPEUTICS INC - ATARA TO RECEIVE UPFRONT PAYMENT OF USD 60 MILLION PLUS TIERED ROYALTIES UP TO LOW DOUBLE-DIGIT PERCENTAGE OF NET SALES.ATARA BIOTHERAPEUTICS INC - COLLABORATION WILL FOCUS ON OFF--SHELF T-CELL IMMUNOTHERAPY ATA3271 FOR HIGH MESOTHELIN-EXPRESSING TUMORS.ATARA BIOTHERAPEUTICS - ATARA TO ALSO PROVIDE TRANSLATIONAL, CLINICAL MANUFACTURING SERVICES TO BE REIMBURSED BY BAYER.ATARA BIOTHERAPEUTICS - FOR A LIMITED PERIOD, BAYER HAS NON-EXCLUSIVE RIGHT TO NEGOTIATE LICENSE FOR ADDITIONAL ATARA CAR T PRODUCT CANDIDATES.

Atara Biotherapeutics Reports Q3 Loss Per Share $0.92

Nov 9 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q3 LOSS PER SHARE $0.92.Q3 EARNINGS PER SHARE ESTIMATE $-1.09 -- REFINITIV IBES DATA.ATARA BIOTHERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF SEPT 30, ARE SUFFICIENT TO FUND PLANNED OPERATIONS INTO 2022.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2020 TOTALED $327.2 MILLION.Q3 EARNINGS PER SHARE VIEW $-1.09 -- REFINITIV IBES DATA.

Atara Biotherapeutics Announces Early-Stage Data From Multiple Sclerosis Treatment

Sept 11 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES ALL PROGRESSIVE MULTIPLE SCLEROSIS PATIENTS WITH SUSTAINED DISABILITY IMPROVEMENT AT SIX MONTHS CONFIRMED IMPROVEMENT AT 12 MONTHS IN THE PHASE 1A STUDY OF ATA188.ATARA BIOTHERAPEUTICS INC - PATIENTS WHO ACHIEVED SDI AT ANY TIMEPOINT MAINTAINED IT AT ALL FUTURE TIMEPOINTS.ATARA BIOTHERAPEUTICS INC - HIGHER PROPORTION OF PATIENTS SHOWING SDI WITH INCREASING DOSE.ATARA BIOTHERAPEUTICS INC - PATIENTS ACHIEVING SDI ALSO DEMONSTRATED TREND TOWARD IMPROVEMENT IN FATIGUE AND PHYSICAL FUNCTION AT 12 MONTHS.ATARA BIOTHERAPEUTICS INC - FIRST AVAILABLE DATA FROM OPEN LABEL EXPANSION SHOW PATIENTS WITH SDI AT 12 MONTHS, MAINTAINED SDI AT LATER TIME POINTS.

Atara Biotherapeutics Reports Q2 Loss Per Share $1.14

Aug 5 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.14.Q2 EARNINGS PER SHARE ESTIMATE $-1.18 -- REFINITIV IBES DATA.

Atara Biotherapeutics Announces Pricing Of $175.5 Million Public Offering

May 27 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $175.5 MILLION PUBLIC OFFERING.ATARA BIOTHERAPEUTICS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 12,633,039 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $11.32 PER SHARE.ATARA - CO ANNOUNCED PRE-FUNDED WARRANTS TO PURCHASE 2.8 MILLION SHARES OF ITS COMMON STOCK AT PURCHASE PRICE OF $11.3199 PER PRE-FUNDED WARRANT SHARE.

Atara Biotherapeutics Announces Proposed Offering Of Common Stock And Pre-Funded Warrants

May 26 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS.

Atara Biotherapeutics Qtrly Loss Per Share $1.36

Feb 27 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT CLINICAL, OPERATIONAL AND STRATEGIC PROGRESS.QTRLY LOSS PER SHARE $1.36.Q4 EARNINGS PER SHARE VIEW $-1.34 -- REFINITIV IBES DATA.

Atara Announces Q3 2019 Financial Results

Nov 7 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT CLINICAL, OPERATIONAL AND STRATEGIC PROGRESS.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2019 TOTALED $282.9 MILLION.QTRLY LOSS PER SHARE $1.31 PER SHARE.Q3 EARNINGS PER SHARE VIEW $-1.44, REVENUE VIEW $0.00 -- REFINITIV IBES DATA.

Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS 2019

Sept 13 (Reuters) - Atara Biotherapeutics Inc <ATRA.O>::ATARA BIOTHERAPEUTICS REPORTS EARLY FINDINGS OF POTENTIAL EFFICACY FROM PHASE 1 STUDY OF ATA188 IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS AT ECTRIMS 2019.ATARA BIOTHERAPEUTICS - SAFETY RESULTS SHOWED THAT ACROSS 4 PLANNED DOSE COHORTS, ATA188 WAS WELL TOLERATED IN PATIENTS WITH PROGRESSIVE FORMS OF MS.ATARA BIOTHERAPEUTICS - TO ADVANCE ATA188 FOR MS PATIENTS & PRESENTING ADDITIONAL EFFICACY AND SAFETY RESULTS FROM THIS STUDY IN 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up